Aurinia Pharmaceuticals Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $287.2M | $5.8M | $-78.0M | $-108.2M | $-181.0M | $-102.7M | $-88.4M | $-53.1M |
| Depreciation & Amortization | $19.4M | $19.4M | $11.6M | $2.7M | $2.8M | $1.4M | — | — |
| Depreciation | $600.0K | $600.0K | $600.0K | $600.0K | $663.0K | $82.0K | $33.0K | $20.0K |
| Amortization | $800.0K | $900.0K | $1.7M | $2.1M | $2.1M | $1.3M | $1.1M | $1.3M |
| Stock-Based Compensation | $14.7M | $31.6M | $45.3M | $32.3M | $31.2M | $17.5M | $7.4M | $6.9M |
| Net Cash from Operating Activities | $135.7M | $44.4M | $-33.5M | $-79.5M | $-157.7M | $-69.9M | $-63.6M | $-51.6M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | $87.0K | $30.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-32.8M | $39.3M | $-6.7M | $-60.6M | $-103.9M | $-158.2M | $7.8M | $-65.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | $98.2M | $40.2M | $0 | $0 | — | — | — | — |
| Net Cash from Financing Activities | $-106.1M | $-49.1M | $-5.1M | $2.4M | $221.1M | $194.4M | $243.9M | $4.0M |
| Net Change in Cash | $-3.2M | $34.6M | $-45.3M | $-137.7M | $-40.5M | $-33.7M | $188.1M | $-47.7M |
| Free Cash Flow | — | — | — | — | — | — | $-63.7M | $-51.6M |